ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

Christina Christoffersen; Emil D. Bartels; Annemarie Aarup Pedersen; Lars Bo Nielsen; Tanja X. Pedersen

doi:10.1016/j.ejphar.2017.03.053

ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

Christina Christoffersen, Emil D. Bartels, Annemarie Aarup Pedersen, Lars Bo Nielsen, Tanja X. Pedersen^*

^*Corresponding author for this work

6 Citations (Scopus)

Abstract

Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.

Original language	English
Journal	European Journal of Pharmacology
Volume	816
Pages (from-to)	154-160
Number of pages	7
ISSN	0014-2999
DOIs	https://doi.org/10.1016/j.ejphar.2017.03.053
Publication status	Published - 5 Dec 2017

Keywords

ApoB
ApoM
Atherosclerosis
Lipoprotein(a)
S1P
Uremia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejphar.2017.03.053

Cite this

@article{90b38ed3581c4ca78fdc1449f79bc955,

title = "ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis",

abstract = "Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.",

keywords = "ApoB, ApoM, Atherosclerosis, Lipoprotein(a), S1P, Uremia",

author = "Christina Christoffersen and Bartels, {Emil D.} and Pedersen, {Annemarie Aarup} and Nielsen, {Lars Bo} and Pedersen, {Tanja X.}",

year = "2017",

month = dec,

day = "5",

doi = "10.1016/j.ejphar.2017.03.053",

language = "English",

volume = "816",

pages = "154--160",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier",

}

TY - JOUR

T1 - ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

AU - Christoffersen, Christina

AU - Bartels, Emil D.

AU - Pedersen, Annemarie Aarup

AU - Nielsen, Lars Bo

AU - Pedersen, Tanja X.

PY - 2017/12/5

Y1 - 2017/12/5

N2 - Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.

AB - Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.

KW - ApoB

KW - ApoM

KW - Atherosclerosis

KW - Lipoprotein(a)

KW - S1P

KW - Uremia

U2 - 10.1016/j.ejphar.2017.03.053

DO - 10.1016/j.ejphar.2017.03.053

M3 - Journal article

C2 - 28351665

AN - SCOPUS:85016566112

SN - 0014-2999

VL - 816

SP - 154

EP - 160

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

ER -

ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this